FDA — authorised 12 February 1959
- Application: NDA011793
- Marketing authorisation holder: NOVARTIS
- Local brand name: ESIDRIX
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Aggressive Blood Pressure control in United States
FDA authorised Aggressive Blood Pressure control on 12 February 1959
Marketing authorisations
FDA — authorised 5 May 1959
- Application: NDA011878
- Marketing authorisation holder: NOVARTIS
- Local brand name: SERPASIL-ESIDRIX #1
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 July 1959
- Application: NDA011971
- Marketing authorisation holder: ABBVIE
- Local brand name: ORETIC
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 January 1961
- Application: NDA012616
- Marketing authorisation holder: PFIZER
- Local brand name: ALDACTAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 December 1962
- Application: NDA013402
- Marketing authorisation holder: MERCK
- Local brand name: ALDORIL D30
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 December 1965
- Application: NDA016042
- Marketing authorisation holder: GLAXOSMITHKLINE LLC
- Local brand name: DYAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 12 January 1973
- Application: ANDA083177
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 May 1974
- Application: NDA011958
- Marketing authorisation holder: MERCK
- Local brand name: HYDROPRES 50
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 July 1974
- Application: ANDA083809
- Marketing authorisation holder: WHITEWORTH TOWN PLSN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 3 October 1974
- Application: ANDA083972
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 January 1975
- Application: ANDA083232
- Marketing authorisation holder: WATSON LABS TEVA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 May 1975
- Application: ANDA084580
- Marketing authorisation holder: BARR
- Local brand name: RESERPINE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 September 1975
- Application: ANDA084658
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 September 1975
- Application: ANDA084579
- Marketing authorisation holder: BARR
- Local brand name: RESERPINE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 June 1976
- Application: ANDA084324
- Marketing authorisation holder: LANNETT CO INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 June 1976
- Application: ANDA084325
- Marketing authorisation holder: LANNETT CO INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 September 1976
- Application: ANDA084776
- Marketing authorisation holder: INWOOD LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 December 1976
- Application: ANDA084912
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 January 1977
- Application: ANDA084878
- Marketing authorisation holder: HIKMA INTL PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 1977
- Application: ANDA083965
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 April 1977
- Application: ANDA084771
- Marketing authorisation holder: BARR
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 April 1977
- Application: ANDA085233
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 3 May 1977
- Application: ANDA085232
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 June 1977
- Application: ANDA085323
- Marketing authorisation holder: SOLVAY
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1977
- Application: ANDA085672
- Marketing authorisation holder: ABC HOLDING
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 July 1977
- Application: ANDA085098
- Marketing authorisation holder: IMPAX LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 August 1977
- Application: ANDA085683
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 August 1977
- Application: ANDA083607
- Marketing authorisation holder: IMPAX LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 September 1977
- Application: ANDA085022
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 January 1978
- Application: ANDA085182
- Marketing authorisation holder: HERITAGE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 1978
- Application: ANDA085347
- Marketing authorisation holder: WHITEWORTH TOWN PLSN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 April 1978
- Application: ANDA085338
- Marketing authorisation holder: WHITEWORTH TOWN PLSN
- Local brand name: H.R.-50
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 13 July 1978
- Application: ANDA085005
- Marketing authorisation holder: ROXANE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 13 July 1978
- Application: ANDA085004
- Marketing authorisation holder: ROXANE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 July 1978
- Application: ANDA086087
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 October 1978
- Application: ANDA086594
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 October 1978
- Application: ANDA086597
- Marketing authorisation holder: PVT FORM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 12 March 1979
- Application: ANDA085219
- Marketing authorisation holder: AUROLIFE PHARMA LLC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 June 1979
- Application: NDA018031
- Marketing authorisation holder: WYETH PHARMS INC
- Local brand name: INDERIDE-80/25
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 3 August 1979
- Application: ANDA086513
- Marketing authorisation holder: MYLAN
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 November 1979
- Application: ANDA084714
- Marketing authorisation holder: ABC HOLDING
- Local brand name: HYDRO-RESERP
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 July 1980
- Application: ANDA086881
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 November 1980
- Application: ANDA087068
- Marketing authorisation holder: OXFORD PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 November 1980
- Application: ANDA087060
- Marketing authorisation holder: DAVA PHARMS INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 November 1980
- Application: ANDA087059
- Marketing authorisation holder: OXFORD PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 April 1981
- Application: ANDA087267
- Marketing authorisation holder: MUTUAL PHARM
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 April 1981
- Application: ANDA084827
- Marketing authorisation holder: SANDOZ
- Local brand name: HYDRO-SERP "25"
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 April 1981
- Application: ANDA085213
- Marketing authorisation holder: SANDOZ
- Local brand name: HYDRO-SERP "50"
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 August 1981
- Application: ANDA085208
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 August 1981
- Application: ANDA085054
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 November 1981
- Application: ANDA087398
- Marketing authorisation holder: WATSON LABS
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 December 1981
- Application: ANDA087610
- Marketing authorisation holder: VANGARD
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 December 1981
- Application: NDA018061
- Marketing authorisation holder: MERCK
- Local brand name: TIMOLIDE 10-25
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 December 1981
- Application: ANDA087655
- Marketing authorisation holder: VANGARD
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 9 March 1982
- Application: ANDA087565
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 April 1982
- Application: ANDA087752
- Marketing authorisation holder: USL PHARMA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 July 1982
- Application: ANDA086369
- Marketing authorisation holder: ALRA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 July 1982
- Application: ANDA083554
- Marketing authorisation holder: ALRA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 1983
- Application: ANDA087511
- Marketing authorisation holder: LEDERLE
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 April 1983
- Application: ANDA086026
- Marketing authorisation holder: WATSON LABS
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 May 1984
- Application: ANDA088200
- Marketing authorisation holder: SANDOZ
- Local brand name: RESERPINE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 July 1984
- Application: ANDA088588
- Marketing authorisation holder: ROXANE
- Local brand name: HYDROCHLOROTHIAZIDE INTENSOL
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 2 July 1984
- Application: ANDA088587
- Marketing authorisation holder: ROXANE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA — authorised 22 October 1984
- Application: NDA019129
- Marketing authorisation holder: AUROBINDO PHARMA USA
- Local brand name: MAXZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 December 1984
- Application: ANDA088829
- Marketing authorisation holder: SUPERPHARM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 December 1984
- Application: ANDA088828
- Marketing authorisation holder: SUPERPHARM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 December 1984
- Application: ANDA088827
- Marketing authorisation holder: SUPERPHARM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 December 1984
- Application: NDA018303
- Marketing authorisation holder: VALIDUS PHARMS
- Local brand name: LOPRESSOR HCT
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 February 1985
- Application: ANDA088923
- Marketing authorisation holder: TEVA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 February 1985
- Application: ANDA088924
- Marketing authorisation holder: TEVA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 August 1985
- Application: ANDA089137
- Marketing authorisation holder: SUPERPHARM
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 November 1985
- Application: ANDA087999
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 January 1986
- Application: ANDA070183
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 January 1986
- Application: ANDA070543
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 January 1986
- Application: ANDA070544
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 January 1986
- Application: ANDA070182
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 April 1986
- Application: ANDA070301
- Marketing authorisation holder: WATSON LABS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 April 1986
- Application: ANDA070305
- Marketing authorisation holder: WATSON LABS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 May 1986
- Application: ANDA070852
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 May 1986
- Application: ANDA070851
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 October 1986
- Application: ANDA070705
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 February 1987
- Application: ANDA070614
- Marketing authorisation holder: STRIDES PHARMA INTL
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 March 1987
- Application: ANDA071127
- Marketing authorisation holder: DURAMED PHARMS BARR
- Local brand name: PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 March 1987
- Application: ANDA071126
- Marketing authorisation holder: DURAMED PHARMS BARR
- Local brand name: PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 April 1987
- Application: ANDA070947
- Marketing authorisation holder: RISING
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 April 1987
- Application: NDA019046
- Marketing authorisation holder: SCHERING
- Local brand name: NORMOZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 August 1987
- Application: ANDA071060
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 August 1987
- Application: ANDA071061
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 December 1987
- Application: ANDA071251
- Marketing authorisation holder: APOTEX INC
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 1988
- Application: ANDA071771
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 March 1988
- Application: ANDA072043
- Marketing authorisation holder: ANI PHARMS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 April 1988
- Application: ANDA071821
- Marketing authorisation holder: TEVA
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 April 1988
- Application: ANDA071819
- Marketing authorisation holder: TEVA
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 April 1988
- Application: ANDA071820
- Marketing authorisation holder: TEVA
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 April 1988
- Application: ANDA071822
- Marketing authorisation holder: TEVA
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 November 1988
- Application: ANDA071851
- Marketing authorisation holder: WATSON LABS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 January 1989
- Application: ANDA071069
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 January 1989
- Application: ANDA070959
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 February 1989
- Application: ANDA070958
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 February 1989
- Application: ANDA070960
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 February 1989
- Application: NDA019778
- Marketing authorisation holder: MERCK
- Local brand name: PRINZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1989
- Application: ANDA072510
- Marketing authorisation holder: DAVA PHARMS INC
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1989
- Application: ANDA072507
- Marketing authorisation holder: DAVA PHARMS INC
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1989
- Application: ANDA072509
- Marketing authorisation holder: DAVA PHARMS INC
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 June 1989
- Application: ANDA072508
- Marketing authorisation holder: DAVA PHARMS INC
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 July 1989
- Application: NDA019888
- Marketing authorisation holder: ALMATICA
- Local brand name: ZESTORETIC
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 December 1991
- Application: ANDA071498
- Marketing authorisation holder: WATSON LABS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 December 1991
- Application: ANDA071501
- Marketing authorisation holder: WATSON LABS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 January 1992
- Application: ANDA081189
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 January 1992
- Application: ANDA081190
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 September 1993
- Application: ANDA073449
- Marketing authorisation holder: WATSON LABS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 March 1995
- Application: ANDA074259
- Marketing authorisation holder: ANI PHARMS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 31 January 1996
- Application: ANDA073467
- Marketing authorisation holder: ANI PHARMS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 April 1996
- Application: ANDA074026
- Marketing authorisation holder: PLIVA
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 June 1996
- Application: ANDA074701
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 5 June 1997
- Application: ANDA074821
- Marketing authorisation holder: SANDOZ
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 27 June 1997
- Application: NDA020729
- Marketing authorisation holder: UCB INC
- Local brand name: UNIRETIC
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 January 1998
- Application: ANDA074970
- Marketing authorisation holder: ANI PHARMS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 6 March 1998
- Application: NDA020818
- Marketing authorisation holder: NOVARTIS
- Local brand name: DIOVAN HCT
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 June 1999
- Application: ANDA075052
- Marketing authorisation holder: DURAMED PHARMS BARR
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 28 December 1999
- Application: NDA020125
- Marketing authorisation holder: PFIZER PHARMS
- Local brand name: ACCURETIC
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 January 2000
- Application: ANDA075640
- Marketing authorisation holder: QUAGEN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 17 November 2000
- Application: NDA021162
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Local brand name: MICARDIS HCT
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 March 2002
- Application: ANDA040412
- Marketing authorisation holder: PRINSTON INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 September 2002
- Application: ANDA075907
- Marketing authorisation holder: PRINSTON INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 31 March 2004
- Application: ANDA076374
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 August 2004
- Application: ANDA076792
- Marketing authorisation holder: MYLAN
- Local brand name: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 March 2005
- Application: ANDA077093
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 August 2006
- Application: NDA021956
- Marketing authorisation holder: CONCORDIA
- Local brand name: DUTOPROL
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 23 January 2007
- Application: ANDA040735
- Marketing authorisation holder: PHARMOBEDIENT
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 February 2007
- Application: ANDA040707
- Marketing authorisation holder: ACTAVIS ELIZABETH
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 16 March 2007
- Application: ANDA040702
- Marketing authorisation holder: LEADING
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 March 2007
- Application: ANDA040810
- Marketing authorisation holder: SUN PHARM INDS INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 July 2007
- Application: ANDA040807
- Marketing authorisation holder: IPCA LABS LTD
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 August 2007
- Application: ANDA078450
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 4 September 2007
- Application: ANDA040809
- Marketing authorisation holder: JUBILANT CADISTA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 September 2007
- Application: ANDA078164
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 11 February 2008
- Application: ANDA078391
- Marketing authorisation holder: JUBILANT CADISTA
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 16 May 2008
- Application: ANDA078389
- Marketing authorisation holder: APOTEX
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 30 May 2008
- Application: ANDA040857
- Marketing authorisation holder: SUN PHARM INDS INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 15 August 2008
- Application: ANDA040907
- Marketing authorisation holder: UNICHEM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 25 September 2008
- Application: ANDA090096
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 2 April 2009
- Application: ANDA079237
- Marketing authorisation holder: IPCA LABS LTD
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 19 January 2010
- Application: ANDA090510
- Marketing authorisation holder: UNICHEM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 6 April 2010
- Application: ANDA090528
- Marketing authorisation holder: TORRENT PHARMS
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 April 2010
- Application: ANDA077732
- Marketing authorisation holder: HIKMA
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 April 2010
- Application: ANDA077157
- Marketing authorisation holder: TEVA PHARMS
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 April 2010
- Application: ANDA091652
- Marketing authorisation holder: MYLAN
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 May 2010
- Application: ANDA078245
- Marketing authorisation holder: LUPIN LTD
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 August 2010
- Application: ANDA090150
- Marketing authorisation holder: APOTEX
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 August 2010
- Application: ANDA077948
- Marketing authorisation holder: CHARTWELL RX
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 October 2010
- Application: ANDA091629
- Marketing authorisation holder: AUROBINDO PHARMA
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 October 2010
- Application: ANDA078385
- Marketing authorisation holder: ZYDUS PHARMS USA INC
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 12 January 2011
- Application: ANDA200180
- Marketing authorisation holder: WATSON LABS
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 April 2011
- Application: ANDA201356
- Marketing authorisation holder: INVAGEN PHARMS
- Local brand name: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 January 2012
- Application: ANDA090654
- Marketing authorisation holder: SUN PHARM INDS
- Local brand name: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 27 January 2012
- Application: ANDA091662
- Marketing authorisation holder: CHARTWELL MOLECULAR
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 17 February 2012
- Application: ANDA091617
- Marketing authorisation holder: ALEMBIC PHARMS LTD
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 9 August 2012
- Application: ANDA202289
- Marketing authorisation holder: MACLEODS PHARMS LTD
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 September 2012
- Application: ANDA201845
- Marketing authorisation holder: JUBILANT CADISTA
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 September 2012
- Application: ANDA078020
- Marketing authorisation holder: MYLAN PHARMS INC
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 24 September 2012
- Application: ANDA202556
- Marketing authorisation holder: ACCORD HLTHCARE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 1 March 2013
- Application: ANDA201682
- Marketing authorisation holder: IPCA LABS LTD
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 12 March 2013
- Application: ANDA091524
- Marketing authorisation holder: APOTEX
- Local brand name: QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 2013
- Application: ANDA202519
- Marketing authorisation holder: AUROBINDO PHARMA LTD
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 2013
- Application: ANDA201662
- Marketing authorisation holder: ALEMBIC
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 2013
- Application: ANDA091519
- Marketing authorisation holder: WATSON LABS TEVA
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 2013
- Application: ANDA078946
- Marketing authorisation holder: LUPIN LTD
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 March 2013
- Application: ANDA203026
- Marketing authorisation holder: APOTEX INC
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 November 2013
- Application: ANDA202870
- Marketing authorisation holder: ALEMBIC
- Local brand name: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 March 2014
- Application: ANDA202150
- Marketing authorisation holder: HERITAGE
- Local brand name: MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 April 2014
- Application: ANDA090651
- Marketing authorisation holder: SUN PHARM INDS INC
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 23 July 2014
- Application: ANDA203018
- Marketing authorisation holder: SCIEGEN PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 February 2016
- Application: ANDA206083
- Marketing authorisation holder: PRINSTON INC
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 21 July 2017
- Application: ANDA204832
- Marketing authorisation holder: UNICHEM
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 6 November 2017
- Application: ANDA204901
- Marketing authorisation holder: PRINSTON INC
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 June 2018
- Application: ANDA208360
- Marketing authorisation holder: ZYDUS PHARMS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 January 2019
- Application: ANDA203561
- Marketing authorisation holder: SCIEGEN PHARMS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 11 February 2019
- Application: ANDA208358
- Marketing authorisation holder: CADILA
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 15 March 2019
- Application: ANDA203000
- Marketing authorisation holder: ZYDUS LIFESCIENCES
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 February 2022
- Application: ANDA216211
- Marketing authorisation holder: RUBICON RESEARCH
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 August 2023
- Application: ANDA204382
- Marketing authorisation holder: AMNEAL PHARMS
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 29 September 2023
- Application: ANDA218015
- Marketing authorisation holder: GRANULES
- Local brand name: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 8 January 2025
- Application: ANDA215789
- Marketing authorisation holder: SENORES PHARMS
- Local brand name: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 28 January 2025
- Application: ANDA214611
- Marketing authorisation holder: MACLEODS PHARMS LTD
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA — authorised 23 April 2026
- Application: ANDA204687
- Marketing authorisation holder: SCIEGEN PHARMS
- Local brand name: VALSARTAN AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085067
- Marketing authorisation holder: INWOOD LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085112
- Marketing authorisation holder: MYLAN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084899
- Marketing authorisation holder: WEST WARD
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070688
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070366
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070365
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070689
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070367
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070854
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070853
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087587
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087586
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084880
- Marketing authorisation holder: MYLAN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085099
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA086504
- Marketing authorisation holder: HALSEY
- Local brand name: HYDRO-D
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA089661
- Marketing authorisation holder: MORTON GROVE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: SOLUTION — ORAL
- Status: approved
FDA
- Application: ANDA071737
- Marketing authorisation holder: VITARINE
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA
- Status: approved
FDA
- Application: ANDA083458
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA083456
- Marketing authorisation holder: WATSON LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071897
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071922
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071898
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071899
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA201616
- Marketing authorisation holder: CIPLA LIMITED
- Local brand name: HYDROCHLOROTHIAZIDE; IRBESARTAN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071900
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA086192
- Marketing authorisation holder: MAST MM
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071923
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087553
- Marketing authorisation holder: UPSHER SMITH
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087540
- Marketing authorisation holder: ASCOT
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087539
- Marketing authorisation holder: ASCOT
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084029
- Marketing authorisation holder: IMPAX LABS
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA074857
- Marketing authorisation holder: NOVARTIS
- Local brand name: TRIAMTERENE AND HYDROCHLOROTHIAZIDE
- Indication: CAPSULE — ORAL
- Status: approved
FDA
- Application: ANDA087948
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071920
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084536
- Marketing authorisation holder: ROXANE
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070829
- Marketing authorisation holder: SANDOZ
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071921
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA088025
- Marketing authorisation holder: ASCOT
- Local brand name: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071553
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087651
- Marketing authorisation holder: USL PHARMA
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071458
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070830
- Marketing authorisation holder: SANDOZ
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071459
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071460
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071461
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071552
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087638
- Marketing authorisation holder: VANGARD
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085152
- Marketing authorisation holder: ELKINS SINN
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA018872
- Marketing authorisation holder: NOVARTIS
- Local brand name: VISKAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA088054
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA071772
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084135
- Marketing authorisation holder: HEATHER
- Local brand name: HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA070368
- Marketing authorisation holder: WATSON LABS
- Local brand name: METHYLDOPA AND HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085974
- Marketing authorisation holder: WATSON LABS
- Local brand name: SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
- Indication: TABLET — ORAL
- Status: approved
Aggressive Blood Pressure control in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Aggressive Blood Pressure control approved in United States?
Yes. FDA authorised it on 12 February 1959; FDA authorised it on 5 May 1959; FDA authorised it on 6 July 1959.
Who is the marketing authorisation holder for Aggressive Blood Pressure control in United States?
NOVARTIS holds the US marketing authorisation.